An observational study in Non-arteritic Anterior Ischemic Optic Neuropathy Obesity and Obesity, sponsored by Istanbul Saglik Bilimleri University. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by Istanbul Saglik Bilimleri University · Observational
How we know · 4 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 353 studies in Obesity with a site in Turkey — 73 open to participants now, 90 under way, 16 of them phase 3. Obesity · Turkey.
Among the 353 studies in Obesity with a site in Turkey, this one is the 145th largest by planned enrollment of the 160 observational ones that give a count, is one of 60 that started in 2026, is one of 160 observational ones, reaches primary completion later than 40 of the 89 other live ones, and was the 336th registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →73 of the 353 studies in Obesity with a site in Turkey are open now. Recruiting first, the newest first:
Pamukkale University · Sites in Turkey
Ages 18–65 · Women only
Gazi University · Sites in Turkey
Ages 50–60 · Women only
Duzce University · Sites in Turkey
Ages 18+
Pamukkale University · Sites in Turkey
Ages 18–60 · Women only
Kocaeli University · Sites in Turkey
Ages 18–65 · Healthy volunteers
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
353 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 27 · Phase 4 3
First in 2005; this study’s year is marked. 60 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 28 is below the median of 115 across 2,159 observational studies indexed under Obesity.
Median enrollment 64 across the 192 interventional studies, 82 across the 160 observational. Of the 237 that completed or were terminated, 7 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 353 have an industry lead sponsor. The 10 most frequent:
Istanbul Saglik Bilimleri University is the lead sponsor of 60 studies on the registry; 15 are open to participants now.
Istanbul Saglik Bilimleri University has 4 studies filed under Obesity — fewer than ten, so there is no comparison to draw.
33 of the studies in Obesity with a site in Turkey that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05556512Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity | 2027-10 |
| NCT07769736Istinye UniversityMotivational Interviews Based on the Five-Step (5A) Model on Obesity Risk | 2026-11 |
| NCT07652151Fundación Pública Andaluza para la gestión de la Investigación en SevillaUNMASK: Unveiling the Pathobiology of Metabolic Dysfunction-Associated Steatotic Liver Disease for the Discovery of Novel Therapeutics and Biomarkers | 2026-11 |
| NCT07846956Istanbul Saglik Bilimleri UniversityNAION in Non-Diabetic Obese Patients Using GLP-1 Receptor Agonists: A Real-World Study | 2026-11-30 |
| NCT07858864Istanbul Saglik Bilimleri UniversityGLP-1 Receptor Agonist Use and Sarcopenia in Obese Individuals Without Diabetes | 2026-11-30 |
Add all 33 to your calendar (.ics) → With an account.
Among the 353 studies in Obesity with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Non-arteritic anterior ischemic optic neuropathy (NAION) is one of the most common causes of sudden, painless, usually unilateral vision loss in adults over 50 years of age, and no proven effective treatment exists. Glucagon-like peptide-1 receptor agonists (GLP-1 RA), such as semaglutide and tirzepatide, are widely used for type 2 diabetes and obesity. Since 2023, case series, cohort studies and regulatory reviews have raised the possibility of an association between semaglutide and NAION, but published evidence is conflicting, and data in non-diabetic obese patients are limited.
This retrospective, single-center, descriptive real-world study will review the existing records of non-diabetic obese adults (BMI > 30) who used a GLP-1 RA and attended the ophthalmology outpatient clinic between January 2025 and February 2026 with at least two eye examinations. The aim is to describe the occurrence and time-related change of NAION and related ophthalmic findings in this population.
Background and rationale: NAION results from impaired perfusion of the optic nerve head, and risk is increased by type 2 diabetes, hypertension, sleep apnea and a small optic disc ("disc at risk"). Proposed mechanisms linking GLP-1 RA to NAION include rapid glycemic and weight change affecting optic nerve perfusion autoregulation, direct effects through GLP-1 receptors present in the retinal ganglion cell layer, and nocturnal hypotension. Studies that examine GLP-1 RA use and NAION together in non-diabetic obese patients were not identified in the literature review by the investigators.
Design: Retrospective descriptive study. Data will be collected by the investigators from the hospital information system; no new examination, parameter or intervention will be requested from patients. Data collection is planned from 30 May 2026 to 30 November 2026, after ethics committee and hospital approval.
Data collected: Age, education level, smoking, alcohol use, weight, height and BMI; ophthalmic findings including Snellen visual acuity, biomicroscopic anterior segment examination, intraocular pressure, fundus examination, direct/indirect light reflex, and retinal nerve fiber layer thickness measured by OCT. Data are recorded on a Descriptive Information Form developed by the investigators.
Sample size: Because no sampling will be performed, all patients meeting the criteria will be included. A power analysis using proportions of 0.38 and 0.09 from previous studies (95% confidence, alpha 0.05, 80% power) gave a required sample of 28 participants.
Statistical analysis: IBM SPSS 26.0. Descriptive statistics (number, percentage, mean, standard deviation); normality by Shapiro-Wilk test, skewness and kurtosis; t-test and/or Mann-Whitney U for two-group comparisons; ANOVA and/or Kruskal-Wallis H for three or more groups; correlation and/or chi-square analysis for associations. Significance level p \< 0.05 with 95% confidence interval.
Confidentiality: Personal information of patients will be kept confidential.
Non-diabetic obese adults using a GLP-1 receptor agonist who attended the ophthalmology outpatient clinic of Kanuni Sultan Suleyman Training and Research Hospital between January 2025 and February 2026.
Inclusion Criteria:
Exclusion Criteria: • Diagnosis of diabetes
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adults aged 18 or older with BMI \> 30 and no diabetes diagnosis, who used a GLP-1 receptor agonist and had at least two ophthalmic examinations with measurements at the clinic between January 2025 and February 2026.
Drug: GLP-1 Receptor Agonist Therapy
Use of a GLP-1 RA prescribed in routine clinical care. No study-specific treatment is given.
This study also gives SemaglutideStudies of SemaglutideSemaglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., TirzepatideStudies of TirzepatideTirzepatide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.
Occurrence of NAION
Number and percentage of participants with a NAION diagnosis recorded in the ophthalmic examination records.
Time frame: Baseline (GLP-1 RA initiation) to final recorded eye examination, up to 14 months
• Change in visual acuity (Snellen chart) between the first and last recorded examination
Change in Snellen best-corrected visual acuity between the first and last recorded ophthalmic examination during the study period.
Time frame: Baseline (GLP-1 RA initiation) to final recorded eye examination, up to 14 months
Plan to share: Undecided
Start is estimated for Sep 2026; primary completion for Nov 2026, 2 months later.
Of 796 non-industry observational studies under Obesity, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 106. This study's planned 2 months is below that.
Counting every sponsor, half of 842 studies reached it within 39 months; a quarter within 17 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Istanbul Saglik Bilimleri University